ACCESS Newswire
30 Jun 2022, 17:19 GMT+10
The U.S. Patent Office has issued decisions rejecting Bright Data's patent validity arguments.
ALEXANDRIA, VA / ACCESSWIRE / June 30, 2022 / A number of proxy industry participants, including Oxylabs, have requested that the United States Patent and Trademark Office ('USPTO') examine the validity of several of Bright Data's patents. Currently, either the USPTO's Central Reexamination Unit ('CRU') or Patent Trial and Appeal Board ('PTAB') is examining the validity of all asserted claims of the five Bright Data patents asserted against Oxylabs in litigation.
At least one challenge to each of the five patents remains active and, in each active investigation, the CRU or PTAB has issued a substantive decision considering and rejecting Bright Data's arguments defending the validity of the asserted claims. The recent decisions of the CRU and PTAB include:
Julius Černiauskas, the CEO of Oxylabs, commented on the current events:
'The USPTO's decisions are not at all surprising. We will continue our pursuit of justice.'
To that end, Oxylabs will not only continue to pursue its own challenges, but Oxylabs will also seek, where permitted by statute, to join proceedings brought by other industry participants to ensure that the USPTO conducts a full and complete analysis of the challenged Bright Data patents.
Oxylabs maintains a dedicated page for its involvement in litigation with Bright Data. For more information, please visit: https://oxylabs.io/legal-timeline
About Oxylabs
Established in 2015, Oxylabs is a premium proxy and public web data acquisition solution provider, enabling companies of all sizes to utilize the power of big data. Constant innovation, a strong and growing patent portfolio, and a focus on ethics have allowed Oxylabs to become a global leader in the data acquisition industry and forge close ties with dozens of Fortune Global 500 companies. In 2022, Oxylabs was named the fastest-growing public data gathering solutions company in Europe in the Financial Times' FT 1000 list.
Media Contact:
Vytautas Kirjazovas
Email: [email protected]
Website: www.oxylabs.io
SOURCE: Oxylabs
Get a daily dose of Raleigh Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Raleigh Times.
More InformationNEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...
KABUL, Afghanistan: Afghanistan, long associated with war and instability, is quietly trying to rebrand itself as a destination for...
SANTA CLARA, California: Executives at Nvidia have quietly been cashing in on the AI frenzy. According to a report by the Financial...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
The U.S. mega-bill would add about 3.3 trillion dollars of deficit in the next decade, higher than the 2.8 trillion dollars of deficit...
Washington [US], July 1 (ANI): US President Donald Trump on Tuesday (local time) reiterated his opposition to electric vehicle (EV)...
Birmingham [UK], July 1 (ANI): Ahead of England's second Test against India at Birmingham, England skipper Ben Stokes spoke on express...
Washington [US], June 30 (ANI): Tech billionaire Elon Musk strongly criticised President Trump's 'big, beautiful bill,' calling it...
GOP leaders are determined to advance Trump's signature agenda. But the bill's complexity, internal party fractures and Democratic...
London [UK], June 28 (ANI): ECB managing director of men's cricket, Rob Key, dropped a subtle hint about tearaway Jofra Archer's return...